81781
document
Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases . OBJECTIVE To determine whether anabolic hormones that affect the musculoskeletal system and active on the immune cells changed during cyclosporin A ( CysA ) therapy . METHODS We carried out a randomized study of patients with rheumatic disease attending the outpatient clinic for rheumatic diseases . Twenty-four patients with chronic arthritis [ 20 with rheumatoid arthritis ( RA ) and 4 with psoriatic arthritis ( PsA ) ] were divided into 2 groups ( 10 RA , 2 PsA ) and randomly given CysA 5 mg/kg daily or hydroxychloroquine ( OH-Chlor ) 6 mg/kg daily in divided doses . RESULTS A significant increase of insulin-like growth factor I ( IGF-I ) ( somatomedin C ) levels and of bone Gla protein was shown after 2 months in the CysA treated group , but not in the OH-Chlor group . A statistically significant correlation was observed between changes of IGF-I levels and of dehydroepiandrosterone sulphate ( DHEAS ) . This finding was confirmed in a further series of 39 patients . No changes were seen in 25 OH-D , 1-25 ( OH ) 2-D3 or parathyroid hormone after CysA . CONCLUSION The effects of CysA on IGF-I may explain some of the clinical , immunologic , and metabolic results during CysA treatment of rheumatic diseases .
81782
Intervention_Pharmacological
Cyclosporin A
81783
Intervention_Pharmacological
cyclosporin A ( CysA ) therapy .
81784
Intervention_Pharmacological
CysA 5
81785
Intervention_Pharmacological
hydroxychloroquine ( OH-Chlor ) 6 mg/kg daily
81786
Outcome_Adverse-effects
somatomedin C insulin-like growth factor I levels
81787
Outcome_Physical
insulin-like growth factor I
81788
Outcome_Physical
bone Gla protein
81789
Outcome_Physical
IGF-I levels and of dehydroepiandrosterone sulphate ( DHEAS )
81790
Participant_Condition
rheumatic disease
81791
Participant_Condition
rheumatic diseases
81792
Participant_Sample-size
Twenty-four
81793
Participant_Condition
chronic arthritis
81794
Participant_Sample-size
20
81795
Participant_Condition
rheumatoid arthritis ( RA )
81796
Participant_Sample-size
4
81797
Participant_Condition
psoriatic arthritis ( PsA )
81798
Participant_Sample-size
39